Liposomal formulations of anthracycline antibiotics

   


1. Peoples' Friendship University
2. Serbsky National Research Centre for Social and Forensic Psychiatry
Type: Review
PubMed Id: 15628591
Year: 2004 vol: 50  issue:5  pages: 412-419
Abstract: Anthracycline antibiotics with significant antitumor activity are widely used for treatment of various oncologic diseases in spite of their poor pharmacokinetics and severe side-effects. To improve the efficacy of treatment of oncologic patients, liposomal formulations of the anthracycline antibiotics, such as Doxil, TLC D-99, and DaunoXome, have been developed. Pharmacokinetic parameters of liposomal doxorubicin and daunorubicin differ markedly from the parameters of their free formulations. Liposomal anthracyclines display a prolonged circulation time, reduced clearance, smaller volume of distribution, and lower toxicity. Doxil and DaunoXome have been licensed for treatment of AIDS-related Kaposi's sarcoma. Entrapment of anthracycline antibiotics into liposomes coupled with monoclonal antibodies enhances their uptake by tumor cells.
Download PDF:
Reference: Berezov T.T., Yaglova N.V., Chekhonin V.P., Zhirkov Yu.A., Liposomal formulations of anthracycline antibiotics, Biomeditsinskaya khimiya, 2004, vol: 50(5), 412-419.
Bibliography
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 2011(Vol:57)
 2010(Vol:56)
 2009(Vol:55)
 2008(Vol:54)
 2007(Vol:53)
 2006(Vol:52)
 2005(Vol:51)
 2004(Vol:50)
 2003(Vol:49)